Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.

Détails

ID Serval
serval:BIB_DF447B7F2FE0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.
Périodique
Leukemia
Auteur⸱e⸱s
Attarbaschi A., Carraro E., Ronceray L., Andrés M., Barzilai-Birenboim S., Bomken S., Brugières L., Burkhardt B., Ceppi F., Chiang AKS, Csoka M., Fedorova A., Jazbec J., Kabickova E., Loeffen J., Mellgren K., Miakova N., Moser O., Osumi T., Pourtsidis A., Rigaud C., Uyttebroeck A., Woessmann W., Pillon M.
Collaborateur⸱rice⸱s
European Intergroup for Childhood Non-Hodgkin's Lymphoma (EICNHL) and the International Berlin-Frankfurt-Münster (i-BFM) Study Group
ISSN
1476-5551 (Electronic)
ISSN-L
0887-6924
Statut éditorial
Publié
Date de publication
02/2021
Peer-reviewed
Oui
Volume
35
Numéro
2
Pages
534-549
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Data on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin's lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980-2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) "other" SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 ± 4%, being worst for patients with preexisting disorders at 28 ± 8%. Five-year OS rates were 38 ± 8%, 59 ± 7%, 79 ± 8%, 34 ± 12%, and 62 ± 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and "other" SMNs (p < 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor prognosis. Moreover, although outcome was favorable in some subtypes of SMNs after childhood NHL (carcinomas, lymphoid neoplasms), other SMNs such as myeloid neoplasms and CNS tumors had a dismal prognosis.
Pubmed
Web of science
Création de la notice
25/05/2020 15:45
Dernière modification de la notice
17/02/2021 7:27
Données d'usage